vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and NORTECH SYSTEMS INC (NSYS). Click either name above to swap in a different company.
AbCellera Biologics Inc. is the larger business by last-quarter revenue ($44.9M vs $30.3M, roughly 1.5× NORTECH SYSTEMS INC). NORTECH SYSTEMS INC runs the higher net margin — 3.0% vs -19.9%, a 22.9% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 5.9%). NORTECH SYSTEMS INC produced more free cash flow last quarter ($5.5M vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs -5.9%).
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
Nortech Systems Inc is a global electronics manufacturing services provider. It delivers end-to-end solutions covering product design, prototyping, full-scale production, and supply chain management for clients operating in medical technology, industrial automation, aerospace and defense, and transportation sectors. It specializes in high-reliability, regulatory-compliant electronic components and assemblies tailored to strict industry standards.
ABCL vs NSYS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $30.3M |
| Net Profit | $-8.9M | $897.0K |
| Gross Margin | — | 16.7% |
| Operating Margin | -63.7% | 3.0% |
| Net Margin | -19.9% | 3.0% |
| Revenue YoY | 788.4% | 5.9% |
| Net Profit YoY | 73.9% | 160.7% |
| EPS (diluted) | $-0.03 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.9M | $30.3M | ||
| Q3 25 | $9.0M | $30.5M | ||
| Q2 25 | $17.1M | $30.7M | ||
| Q1 25 | $4.2M | $26.9M | ||
| Q4 24 | $5.0M | $28.6M | ||
| Q3 24 | $6.5M | $31.4M | ||
| Q2 24 | $7.3M | $33.9M | ||
| Q1 24 | $10.0M | $34.2M |
| Q4 25 | $-8.9M | $897.0K | ||
| Q3 25 | $-57.1M | $-146.0K | ||
| Q2 25 | $-34.7M | $313.0K | ||
| Q1 25 | $-45.6M | $-1.3M | ||
| Q4 24 | — | $-1.5M | ||
| Q3 24 | $-51.1M | $-739.0K | ||
| Q2 24 | $-36.9M | $157.0K | ||
| Q1 24 | $-40.6M | $765.0K |
| Q4 25 | — | 16.7% | ||
| Q3 25 | — | 16.5% | ||
| Q2 25 | — | 15.8% | ||
| Q1 25 | — | 11.4% | ||
| Q4 24 | — | 9.9% | ||
| Q3 24 | — | 12.2% | ||
| Q2 24 | — | 13.6% | ||
| Q1 24 | — | 15.9% |
| Q4 25 | -63.7% | 3.0% | ||
| Q3 25 | -851.8% | 3.1% | ||
| Q2 25 | -290.2% | 2.4% | ||
| Q1 25 | -1479.6% | -6.0% | ||
| Q4 24 | — | -4.3% | ||
| Q3 24 | -1439.4% | -1.5% | ||
| Q2 24 | -1276.2% | 1.0% | ||
| Q1 24 | -551.5% | 3.4% |
| Q4 25 | -19.9% | 3.0% | ||
| Q3 25 | -637.8% | -0.5% | ||
| Q2 25 | -203.3% | 1.0% | ||
| Q1 25 | -1077.2% | -4.9% | ||
| Q4 24 | — | -5.2% | ||
| Q3 24 | -785.4% | -2.4% | ||
| Q2 24 | -504.3% | 0.5% | ||
| Q1 24 | -408.0% | 2.2% |
| Q4 25 | $-0.03 | $0.32 | ||
| Q3 25 | $-0.19 | $-0.05 | ||
| Q2 25 | $-0.12 | $0.12 | ||
| Q1 25 | $-0.15 | $-0.48 | ||
| Q4 24 | — | $-0.51 | ||
| Q3 24 | $-0.17 | $-0.27 | ||
| Q2 24 | $-0.13 | $0.05 | ||
| Q1 24 | $-0.14 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.5M | $1.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $966.9M | $34.5M |
| Total Assets | $1.4B | $71.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $128.5M | $1.7M | ||
| Q3 25 | $83.2M | $1.3M | ||
| Q2 25 | $92.4M | $652.0K | ||
| Q1 25 | $159.3M | $1.2M | ||
| Q4 24 | $156.3M | $916.0K | ||
| Q3 24 | $126.6M | $1.2M | ||
| Q2 24 | $148.3M | $1.5M | ||
| Q1 24 | $123.6M | $4.0M |
| Q4 25 | $966.9M | $34.5M | ||
| Q3 25 | $964.0M | $33.4M | ||
| Q2 25 | $1.0B | $33.4M | ||
| Q1 25 | $1.0B | $32.8M | ||
| Q4 24 | $1.1B | $34.0M | ||
| Q3 24 | $1.1B | $35.7M | ||
| Q2 24 | $1.1B | $36.1M | ||
| Q1 24 | $1.1B | $36.0M |
| Q4 25 | $1.4B | $71.9M | ||
| Q3 25 | $1.4B | $74.8M | ||
| Q2 25 | $1.4B | $74.8M | ||
| Q1 25 | $1.3B | $73.5M | ||
| Q4 24 | $1.4B | $72.4M | ||
| Q3 24 | $1.4B | $77.0M | ||
| Q2 24 | $1.4B | $76.3M | ||
| Q1 24 | $1.5B | $75.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.7M | $5.6M |
| Free Cash FlowOCF − Capex | $-44.6M | $5.5M |
| FCF MarginFCF / Revenue | -99.4% | 18.0% |
| Capex IntensityCapex / Revenue | 21.9% | 0.5% |
| Cash ConversionOCF / Net Profit | — | 6.25× |
| TTM Free Cash FlowTrailing 4 quarters | $-174.1M | $2.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.7M | $5.6M | ||
| Q3 25 | $-52.6M | $-92.0K | ||
| Q2 25 | $-32.4M | $157.0K | ||
| Q1 25 | $-11.6M | $-2.9M | ||
| Q4 24 | $-108.6M | $793.0K | ||
| Q3 24 | $-28.9M | $-1.6M | ||
| Q2 24 | $-30.0M | $-4.3M | ||
| Q1 24 | $-41.7M | $2.8M |
| Q4 25 | $-44.6M | $5.5M | ||
| Q3 25 | $-61.5M | $-242.0K | ||
| Q2 25 | $-45.8M | $58.0K | ||
| Q1 25 | $-22.2M | $-3.2M | ||
| Q4 24 | $-187.0M | $503.0K | ||
| Q3 24 | $-47.4M | $-1.6M | ||
| Q2 24 | $-50.1M | $-4.6M | ||
| Q1 24 | $-65.8M | $2.1M |
| Q4 25 | -99.4% | 18.0% | ||
| Q3 25 | -687.0% | -0.8% | ||
| Q2 25 | -267.9% | 0.2% | ||
| Q1 25 | -524.0% | -11.9% | ||
| Q4 24 | -3702.8% | 1.8% | ||
| Q3 24 | -728.4% | -5.2% | ||
| Q2 24 | -683.8% | -13.5% | ||
| Q1 24 | -661.5% | 6.1% |
| Q4 25 | 21.9% | 0.5% | ||
| Q3 25 | 99.7% | 0.5% | ||
| Q2 25 | 78.2% | 0.3% | ||
| Q1 25 | 251.1% | 1.0% | ||
| Q4 24 | 1552.7% | 1.0% | ||
| Q3 24 | 284.6% | 0.1% | ||
| Q2 24 | 274.6% | 0.8% | ||
| Q1 24 | 242.5% | 2.2% |
| Q4 25 | — | 6.25× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.50× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -27.30× | ||
| Q1 24 | — | 3.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABCL
Segment breakdown not available.
NSYS
| Medical Imaging | $11.4M | 37% |
| Medical Device | $8.0M | 26% |
| Industrial | $7.3M | 24% |
| Aerospace And Defense | $3.7M | 12% |
